Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
(FY)Dec 31, 2024 | (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | |
---|---|---|---|---|
Total revenue | 14.38%193.28M | 35.68%168.99M | 38.59%124.55M | 89.86M |
Operating revenue | 13.76%206.74M | 33.97%181.73M | 37.80%135.64M | --98.43M |
Excise taxes | 2.57%11.68M | 22.76%11.39M | 28.62%9.28M | --7.21M |
Cost of revenue | 6.98%70.75M | 25.23%66.14M | 47.39%52.81M | 35.83M |
Gross profit | 19.14%122.53M | 43.38%102.85M | 32.76%71.73M | 54.03M |
Operating expense | -15.98%87.71M | 29.62%104.39M | 2.39%80.54M | 78.66M |
Selling and administrative expenses | -29.65%85.82M | 51.12%121.98M | 2.60%80.72M | --78.67M |
-Selling and marketing expense | -2.58%28.08M | 5.32%28.83M | 21.12%27.37M | --22.6M |
-General and administrative expense | -38.03%57.73M | 74.62%93.16M | -4.86%53.35M | --56.07M |
Other operating expenses | 110.76%1.89M | -9,568.68%-17.6M | -1,416.67%-182K | ---12K |
Operating profit | 2,362.44%34.82M | 82.52%-1.54M | 64.25%-8.8M | -24.63M |
Net non-operating interest income expense | -238.85%-70.61M | -3,802.06%-20.84M | 94.87%-534K | -10.4M |
Non-operating interest income | 43.55%1.15M | 25.24%799K | 202.37%638K | --211K |
Non-operating interest expense | 266.79%71.76M | 23.72%19.56M | 117.81%15.81M | --7.26M |
Total other finance cost | -100.29%-6K | 114.15%2.07M | -536.65%-14.64M | --3.35M |
Other net income (expense) | 85.17%-32.92M | -115.27%-221.93M | -165.46%-103.09M | -38.84M |
Gain on sale of security | -292.56%-12.06M | 6,289.80%6.26M | -65.97%98K | --288K |
Special income (charges) | 90.86%-20.86M | -121.13%-228.19M | -163.76%-103.19M | ---39.12M |
-Less:Restructuring and merger&acquisition | -93.78%2.52M | 148.77%40.54M | -49.66%16.29M | --32.37M |
-Less:Impairment of capital assets | 61.27%18.34M | -86.91%11.37M | 1,185.84%86.9M | --6.76M |
-Less:Other special charges | ---- | --176.28M | ---- | ---- |
Income before tax | 71.88%-68.71M | -117.29%-244.3M | -52.21%-112.43M | -73.86M |
Income tax | 167.09%9.5M | 100.34%3.56M | -53.69%1.78M | 3.84M |
Net income | 68.45%-78.21M | -117.03%-247.86M | -46.99%-114.21M | -77.7M |
Net income continuous Operations | 68.45%-78.21M | -117.03%-247.86M | -46.99%-114.21M | ---77.7M |
Minority interest income | 16.28%7.96M | 3,290.59%6.85M | 202K | 0 |
Net income attributable to the parent company | 66.17%-86.17M | -122.63%-254.71M | -47.25%-114.41M | -77.7M |
Preferred stock dividends | ||||
Other preferred stock dividends | ||||
Net income attributable to common stockholders | 66.17%-86.17M | -122.63%-254.71M | -47.25%-114.41M | -77.7M |
Basic earnings per share | 75.96%-2.58 | -160.10%-10.73 | -47.25%-4.1253 | -2.8017 |
Diluted earnings per share | 75.96%-2.58 | -160.10%-10.73 | -47.25%-4.1253 | -2.8017 |
Dividend per share | ||||
Currency Unit | BRL | BRL | BRL | BRL |
Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- |